MA35724B1 - Molécules d'anticorps ayant une spécificité pour des déterminants antigéniques de ox40 humain, des utilisations thérapeutiques de ces molécules d'anticorps et leurs procédés de production. - Google Patents
Molécules d'anticorps ayant une spécificité pour des déterminants antigéniques de ox40 humain, des utilisations thérapeutiques de ces molécules d'anticorps et leurs procédés de production.Info
- Publication number
- MA35724B1 MA35724B1 MA37104A MA37104A MA35724B1 MA 35724 B1 MA35724 B1 MA 35724B1 MA 37104 A MA37104 A MA 37104A MA 37104 A MA37104 A MA 37104A MA 35724 B1 MA35724 B1 MA 35724B1
- Authority
- MA
- Morocco
- Prior art keywords
- antibody molecules
- specificity
- human
- methods
- therapeutic uses
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
L'invention concerne des molécules d'anticorps ayant une spécificité pour des déterminants antigéniques de ox40 humain, des utilisations thérapeutiques de ces molécules d'anticorps et leurs procédés de production.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161558545P | 2011-11-11 | 2011-11-11 | |
| PCT/EP2012/072325 WO2013068563A2 (fr) | 2011-11-11 | 2012-11-09 | Molécules d'anticorps ayant une spécificité pour ox40 humain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA35724B1 true MA35724B1 (fr) | 2014-12-01 |
Family
ID=47388492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA37104A MA35724B1 (fr) | 2011-11-11 | 2014-06-05 | Molécules d'anticorps ayant une spécificité pour des déterminants antigéniques de ox40 humain, des utilisations thérapeutiques de ces molécules d'anticorps et leurs procédés de production. |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | US9040048B2 (fr) |
| EP (1) | EP2776469B1 (fr) |
| JP (1) | JP6367714B2 (fr) |
| KR (1) | KR102071054B1 (fr) |
| CN (1) | CN103946240B (fr) |
| AP (1) | AP2014007668A0 (fr) |
| AR (1) | AR088820A1 (fr) |
| AU (1) | AU2012333997B2 (fr) |
| BR (1) | BR112014011404A2 (fr) |
| CA (1) | CA2855174C (fr) |
| CL (1) | CL2014001193A1 (fr) |
| CO (1) | CO7010784A2 (fr) |
| CY (1) | CY1122073T1 (fr) |
| DK (1) | DK2776469T3 (fr) |
| EA (1) | EA035112B1 (fr) |
| EC (1) | ECSP14000329A (fr) |
| ES (1) | ES2737998T3 (fr) |
| HR (1) | HRP20191219T1 (fr) |
| HU (1) | HUE044333T2 (fr) |
| IL (1) | IL232420B (fr) |
| LT (1) | LT2776469T (fr) |
| MA (1) | MA35724B1 (fr) |
| MX (1) | MX358391B (fr) |
| MY (1) | MY183795A (fr) |
| PE (1) | PE20141995A1 (fr) |
| PH (1) | PH12014500946A1 (fr) |
| PL (1) | PL2776469T3 (fr) |
| PT (1) | PT2776469T (fr) |
| SG (1) | SG11201402093RA (fr) |
| SI (1) | SI2776469T1 (fr) |
| TN (1) | TN2014000206A1 (fr) |
| TR (1) | TR201910721T4 (fr) |
| TW (1) | TWI588155B (fr) |
| UA (1) | UA112203C2 (fr) |
| WO (1) | WO2013068563A2 (fr) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010216152B2 (en) * | 2009-02-17 | 2015-05-14 | Ucb Biopharma Sprl | Antibody molecules having specificity for human OX40 |
| WO2011030107A1 (fr) * | 2009-09-10 | 2011-03-17 | Ucb Pharma S.A. | Anticorps multivalents |
| LT2609118T (lt) | 2010-08-23 | 2017-04-25 | Board Of Regents, The University Of Texas System | Anti-ox40 antikūnai ir jų panaudojimo būdai |
| GB201116092D0 (en) | 2011-09-16 | 2011-11-02 | Bioceros B V | Antibodies and uses thereof |
| BR112014006175B1 (pt) * | 2011-09-16 | 2020-02-11 | Ucb Pharma S.A. | Anticorpos capazes de neutralisar as exotoxinas principais tcda e tcdb de clostridium difficile |
| GB201223276D0 (en) * | 2012-12-21 | 2013-02-06 | Ucb Pharma Sa | Antibodies and methods of producing same |
| RS57840B1 (sr) | 2013-03-18 | 2018-12-31 | Biocerox Prod Bv | Humanizovana anti-cd 134 (ox40) antitela i njihove upotrebe |
| WO2015041515A1 (fr) | 2013-09-19 | 2015-03-26 | N.V. Nutricia | Procédé amélioré d'humanisation de lait animal écrémé |
| KR20160146747A (ko) | 2014-03-31 | 2016-12-21 | 제넨테크, 인크. | 항혈관신생제 및 ox40 결합 효능제를 포함하는 조합 요법 |
| GB201411320D0 (en) | 2014-06-25 | 2014-08-06 | Ucb Biopharma Sprl | Antibody construct |
| GB201412658D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
| PL3265123T3 (pl) | 2015-03-03 | 2023-03-13 | Kymab Limited | Przeciwciała, zastosowania i sposoby |
| WO2016145085A2 (fr) | 2015-03-09 | 2016-09-15 | Celldex Therapeutics, Inc. | Agonistes cd27 |
| GB201506868D0 (en) * | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method for protein purification |
| GB201506869D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
| GB201506870D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
| EP3292152A1 (fr) | 2015-05-07 | 2018-03-14 | Agenus Inc. | Anticorps anti-ox40 et procédés d'utilisation de ceux-ci |
| GB201601077D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibody molecule |
| GB201601073D0 (en) * | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies |
| MY206406A (en) * | 2015-10-02 | 2024-12-16 | Hoffmann La Roche | Bispecific antibodies specific for a costimulatory tnf receptor |
| WO2017063162A1 (fr) * | 2015-10-15 | 2017-04-20 | 苏州丁孚靶点生物技术有限公司 | Anticorps anti-ox40 et son application |
| WO2017096179A1 (fr) | 2015-12-02 | 2017-06-08 | Agenus Inc. | Anticorps et leurs méthodes d'utilisation |
| GB201521382D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
| GB201521389D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Method |
| CA3006963A1 (fr) * | 2015-12-03 | 2017-06-08 | Ludwig Institute For Cancer Research Ltd. | Anticorps anti-ox40 et leurs procedes d'utilisation |
| KR102379464B1 (ko) | 2016-06-20 | 2022-03-29 | 키맵 리미티드 | 항-pd-l1 항체 |
| WO2018083248A1 (fr) | 2016-11-03 | 2018-05-11 | Kymab Limited | Anticorps, combinaisons comprenant des anticorps, biomarqueurs, utilisations et procédés |
| CA3041340A1 (fr) * | 2016-11-09 | 2018-05-17 | Agenus Inc. | Anticorps anti-ox40, anticorps anti-gitr, et leurs procedes d'utilisation |
| EP3824906A1 (fr) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Formulations d'anticorps anti-tnf alpha |
| WO2019241730A2 (fr) | 2018-06-15 | 2019-12-19 | Flagship Pioneering Innovations V, Inc. | Augmentation de l'activité immunitaire par modulation de facteurs de signalisation post-cellulaires |
| MA55805A (fr) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V Inc | Métodes de modulation de l'activité immunitaire |
| SG11202112846RA (en) | 2019-08-02 | 2021-12-30 | UCB Biopharma SRL | Methods for purifying antibodies |
| JP2023509359A (ja) | 2019-12-17 | 2023-03-08 | フラグシップ パイオニアリング イノベーションズ ブイ,インコーポレーテッド | 鉄依存性細胞分解の誘導物質との併用抗癌療法 |
| PE20221506A1 (es) | 2019-12-17 | 2022-10-04 | Amgen Inc | Agonista doble de interleucina-2/receptor de tnf para uso en terapia |
| CN116096906A (zh) | 2020-06-29 | 2023-05-09 | 旗舰创业创新五公司 | 工程化以促进萨诺传递的病毒及其在治疗癌症中的用途 |
| EP4313109A1 (fr) | 2021-03-31 | 2024-02-07 | Flagship Pioneering Innovations V, Inc. | Polypeptides de thanotransmission et leur utilisation dans le traitement du cancer |
| US20240316104A1 (en) | 2021-06-29 | 2024-09-26 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
| WO2024077191A1 (fr) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Molécules d'acide nucléique codant pour des trif et des polypeptides supplémentaires et leur utilisation dans le traitement du cancer |
| WO2024151687A1 (fr) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Commutateurs génétiques et leur utilisation dans le traitement du cancer |
| WO2025248017A1 (fr) | 2024-05-31 | 2025-12-04 | UCB Biopharma SRL | Procédé de purification de protéines de recombinaison |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| DK336987D0 (da) | 1987-07-01 | 1987-07-01 | Novo Industri As | Immobiliseringsmetode |
| GB8719042D0 (en) | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
| GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8907617D0 (en) | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
| GB9120467D0 (en) | 1991-09-26 | 1991-11-06 | Celltech Ltd | Anti-hmfg antibodies and process for their production |
| US5821332A (en) | 1993-11-03 | 1998-10-13 | The Board Of Trustees Of The Leland Stanford Junior University | Receptor on the surface of activated CD4+ T-cells: ACT-4 |
| FR2716640B1 (fr) | 1994-02-28 | 1996-05-03 | Procedes Machines Speciales | Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion. |
| US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
| GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| US6908963B2 (en) | 2001-10-09 | 2005-06-21 | Nektar Therapeutics Al, Corporation | Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith |
| GB0124317D0 (en) | 2001-10-10 | 2001-11-28 | Celltech R&D Ltd | Biological products |
| US20040146948A1 (en) | 2002-10-18 | 2004-07-29 | Centenary Institute Of Cancer Medicine And Cell Biology | Compositions and methods for targeting antigen-presenting cells with antibody single-chain variable region fragments |
| GB0303337D0 (en) | 2003-02-13 | 2003-03-19 | Celltech R&D Ltd | Biological products |
| ITRM20030601A1 (it) | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| ITRM20050290A1 (it) | 2005-06-07 | 2006-12-08 | Lay Line Genomics Spa | Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato. |
| TWI461436B (zh) | 2005-11-25 | 2014-11-21 | Kyowa Hakko Kirin Co Ltd | 人類cd134(ox40)之人類單株抗體及其製造及使用方法 |
| WO2007065433A2 (fr) | 2005-12-05 | 2007-06-14 | Symphogen A/S | Anticorps polyclonal recombinant anti-orthopoxvirus |
| US20070224627A1 (en) | 2006-03-23 | 2007-09-27 | Lawrence Horowitz | Facilitation of translocation of molecules through the gastrointestinal tract |
| KR20100014588A (ko) | 2007-02-27 | 2010-02-10 | 제넨테크, 인크. | 길항제 ox40 항체 및 염증성 및 자가면역 질환의 치료에서의 이의 용도 |
| EP2535350B1 (fr) | 2007-09-26 | 2018-01-24 | UCB Biopharma SPRL | Fusions d'anticorps à double spécificité |
| US10407513B2 (en) * | 2008-09-26 | 2019-09-10 | Ucb Biopharma Sprl | Biological products |
| AU2010216152B2 (en) * | 2009-02-17 | 2015-05-14 | Ucb Biopharma Sprl | Antibody molecules having specificity for human OX40 |
| WO2011030107A1 (fr) | 2009-09-10 | 2011-03-17 | Ucb Pharma S.A. | Anticorps multivalents |
| GB201005063D0 (en) | 2010-03-25 | 2010-05-12 | Ucb Pharma Sa | Biological products |
| GB201000467D0 (en) | 2010-01-12 | 2010-02-24 | Ucb Pharma Sa | Antibodies |
| JP5522668B2 (ja) | 2010-02-03 | 2014-06-18 | 株式会社ブリヂストン | タイヤ構成部材の切断装置及び製造方法 |
| JP6411214B2 (ja) * | 2011-11-11 | 2018-10-24 | ユーシービー バイオファルマ エスピーアールエル | アルブミン結合抗体及びその結合断片 |
-
2012
- 2012-09-11 UA UAA201404941A patent/UA112203C2/uk unknown
- 2012-11-08 US US13/672,077 patent/US9040048B2/en not_active Expired - Fee Related
- 2012-11-09 TR TR2019/10721T patent/TR201910721T4/tr unknown
- 2012-11-09 WO PCT/EP2012/072325 patent/WO2013068563A2/fr not_active Ceased
- 2012-11-09 HU HUE12803508 patent/HUE044333T2/hu unknown
- 2012-11-09 AP AP2014007668A patent/AP2014007668A0/xx unknown
- 2012-11-09 LT LTEP12803508.6T patent/LT2776469T/lt unknown
- 2012-11-09 EA EA201400565A patent/EA035112B1/ru not_active IP Right Cessation
- 2012-11-09 BR BR112014011404A patent/BR112014011404A2/pt not_active Application Discontinuation
- 2012-11-09 MX MX2014005564A patent/MX358391B/es active IP Right Grant
- 2012-11-09 PE PE2014000673A patent/PE20141995A1/es active IP Right Grant
- 2012-11-09 SI SI201231633T patent/SI2776469T1/sl unknown
- 2012-11-09 CN CN201280055398.8A patent/CN103946240B/zh not_active Expired - Fee Related
- 2012-11-09 SG SG11201402093RA patent/SG11201402093RA/en unknown
- 2012-11-09 MY MYPI2014701189A patent/MY183795A/en unknown
- 2012-11-09 AU AU2012333997A patent/AU2012333997B2/en not_active Ceased
- 2012-11-09 TW TW101141760A patent/TWI588155B/zh not_active IP Right Cessation
- 2012-11-09 HR HRP20191219TT patent/HRP20191219T1/hr unknown
- 2012-11-09 DK DK12803508.6T patent/DK2776469T3/da active
- 2012-11-09 AR ARP120104230A patent/AR088820A1/es unknown
- 2012-11-09 PT PT12803508T patent/PT2776469T/pt unknown
- 2012-11-09 JP JP2014540489A patent/JP6367714B2/ja not_active Expired - Fee Related
- 2012-11-09 PH PH1/2014/500946A patent/PH12014500946A1/en unknown
- 2012-11-09 CA CA2855174A patent/CA2855174C/fr not_active Expired - Fee Related
- 2012-11-09 PL PL12803508T patent/PL2776469T3/pl unknown
- 2012-11-09 KR KR1020147015520A patent/KR102071054B1/ko not_active Expired - Fee Related
- 2012-11-09 EP EP12803508.6A patent/EP2776469B1/fr active Active
- 2012-11-09 ES ES12803508T patent/ES2737998T3/es active Active
-
2014
- 2014-05-01 IL IL232420A patent/IL232420B/en active IP Right Grant
- 2014-05-07 CL CL2014001193A patent/CL2014001193A1/es unknown
- 2014-05-08 EC ECIEPI2014329A patent/ECSP14000329A/es unknown
- 2014-05-08 CO CO14099147A patent/CO7010784A2/es unknown
- 2014-05-08 TN TNP2014000206A patent/TN2014000206A1/en unknown
- 2014-06-05 MA MA37104A patent/MA35724B1/fr unknown
-
2015
- 2015-04-27 US US14/697,142 patent/US9873735B2/en not_active Expired - Fee Related
-
2019
- 2019-07-23 CY CY20191100781T patent/CY1122073T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2398498A4 (fr) | Molécules d'anticorps ayant une spécificité pour ox40 humain | |
| CY1122073T1 (el) | Μορια αντισωματος που εχουν εξειδικευση για τον ανθρωπινο οχ40 | |
| MA34907B1 (fr) | Molécules d'anticorps se liant à il-17a et il-17f | |
| CY1122490T1 (el) | Αντισωματα κατα του ανθρωπινου cd38 | |
| CY1120413T1 (el) | Ειδικα εξανθρωπισμενα αντισωματα στην πρωτοϊνιδιακη μορφη του βητα-αμυλοειδους πεπτιδιου | |
| MA37538A2 (fr) | Anticorps et immunoconjugués anti-ly6e et procédés d'utilisation | |
| EA201891833A1 (ru) | Комбинация для лечения амиотрофического бокового склероза или родственных болезней | |
| EA200900040A1 (ru) | Молекулы антител, которые связываются с человеческим il-17 | |
| EA201101303A1 (ru) | Молекулы антител, обладающие связывающей специфичностью в отношении il-13 человека | |
| EA201290988A1 (ru) | Стереоселективный синтез фосфорсодержащих активных соединений | |
| MA33537B1 (fr) | Anticorps anti-cdcp1 humanisés | |
| PH12017500864A1 (en) | Anti-notch1 antibodies | |
| TW200728466A (en) | Antibody molecules having specificity for human IL-6 | |
| EA201591191A1 (ru) | Антитела против ntb-a и связанные с ними композиции и способы | |
| CR20150153A (es) | Tratamiento para artitris reumatoide | |
| GB2496801A (en) | A method of treating alzheimer's disease | |
| EA201190313A1 (ru) | Замещенные пиперидины | |
| EP2892555A4 (fr) | Immunogènes d'anticorps de vih-1 largement neutralisants, procédés de génération et utilisations associés | |
| TN2013000068A1 (en) | Anti-vegfr-3 antibody compositions | |
| MA35947B1 (fr) | Anticorps et immunoconjugués anti-lgr5 | |
| TR201905240T4 (tr) | LIV-1'e hümanize edilmiş antikorlar ve bunların kanserin tedavisinde kullanımı. |